CERC is a long-standing partner of EuroPCR. In this year of change, there was no way we were going to miss the event! 2 CERC trials are presented: EBC MAIN (read pg. 2), a late-breaking trial, Wednesday, May 19, 10:20 – 10:40, Main Arena, « EBC MAIN – the European Bifurcation Club left main coronary bifurcation study” but also via a CERC interview with David Hildick-Smith, entitled « EBC Main: behind the curtain », available in the Videos On Demand section. Electroducer, a novel stimulation device (read pg. 3). This innovation was selected for the « Jon Dehaan Foundation Prize » competition. The presentation is available in an on-demand video entitled « Universal direct wire pacing (DWP) device to simplify THV and complex PC” and presented by Nicolas Dumonteil. Come and join us at EuroPCR...
Our latest studies and publications, our new services… Discover all the news for the first quarter of the year in the latest issue of our Chronicle. 👉Follow this...
Learn about our COMPARE-ABSORB trial and Click here to download the results presented at CRT 2021. ...
CERC is happy to announce the integration of a new function in the ARC HBR smartphone app. Its aim is to evaluate the individual trade-off between bleeding and thrombotic events in PCI patients at HBR. In 4 quick steps (see picture below), the user gets a clear result. A very helpful tool to tailor management of the HBR patients. To learn more about the method, read « Assessing the Risk of Bleeding vs Thrombotic Events at High Bleeding Risk After Coronary Stent Implantation » by Philip Urban, John Gregson, Ruth Owen et al. 👉 Available on App Store and Google...
By Olivier Varenne, PI of the trial The CAOCT study is an investigator-initiated trial held thanks to a grant from Abbott Vascular and consists of a prospective, multi-centre, single cohort, diagnostic accuracy study. The study aims to compare the angio to the OCT to evaluate the ability to detect the culprit lesion. 131 patients, survivors of OHCA will be included in France, Serbia and Belgium. The trial is undergoing regulatory review. Out-of-hospital cardiac arrest (OHCA) is a leading cause of sudden death in Europe and the United States. Mortality is currently close to 40% among those patients who had been successfully resuscitated after OHCA associated with ventricular fibrillation or pulseless ventricular tachycardia. Coronary artery disease is observed in up to 70% of patients with OHCA and immediate coronary angiography. Current European and American guidelines recommend immediate coronary angiography with primary angioplasty in OHCA patients with ST-segment elevation on ECG after successful resuscitation. However, in patients with OHCA but without ST-segment elevation on ECG after return of spontaneous circulation (ROSC), systematic immediate coronary angiography has not been shown to improve 90-day survival when compared to delayed angiography. Moreover, detection of significant coronary artery disease in survivors of an OHCA does not necessarily translate into a causal link to explain cardiac arrest. Furthermore, the identification of the culprit lesion by coronary angiography among patients with an acute coronary syndrome (ACS) and no OHCA is challenging. In the Coronary Angiography after cardiac arrest (COACT) trial, a randomized controlled trial comparing immediate versus delayed coronary angiography after OHCA in patients without ST segment elevation on ECG, some degree of coronary artery disease was...
« Medical imaging has advanced considerably over the last 40 years since the first angioplasty was performed and now plays an important role in the evaluation of existing and novel therapies. The Corelab at CERC provides expert, centralized and independent analysis of patient imaging data. This data informs the medical community and is used for CE mark approvals and FDA submissions. We work with medical experts across a range of specialties to provide Corelab services for angiographic, CT, Echo, OCT, IVUS and ECG images. Over the years we have analysed imaging data of thousands of patients in multiple clinical trials and registries and our data has been presented at hundreds of international meetings. No, we don’t spend all our time locked in dark rooms looking at screens! We work with our sponsors to determine the type of imaging data and analysis that will best answer their research question. We work with our project managers to develop a corelab package outlining to the clinical investigation sites the process for acquiring and transferring the imaging data and we work with our data managers to develop the CRF so that we have all the data required to answer the research question posed by the sponsor. » Antoinette Neylon, Corelab Manager @CERC ...
